Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05375656
Other study ID # F15319-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2022
Est. completion date May 7, 2022

Study information

Verified date May 2022
Source Steno Diabetes Center Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Around 10% has type 2 diabetes in Greenland, despite being a practically unknown disease only six decades ago. The drastic increase is of great concern, especially considering the transition that have occurred during the same decades going from a fisher-hunter lifestyle towards a more western lifestyle. Today, traditional marine foods are still increasingly being replaced by imported foods high in refined sugar (sucrose) and starch. Furthermore, recent studies discovered that the Greenlandic population harbors a different genetic architecture behind type 2 diabetes. Hence, obtaining more knowledge on interactions between lifestyle, genetics, and metabolism is therefore crucial in order to ameliorate the growing curve, or maybe even turn it around. Sucrose intolerance is in general rare; however, it is a common condition in Greenland and other Inuit populations. Here it is caused by a genetic variant in the sucrase-isomaltase (SI) gene, resulting in complete loss of enzyme function and hence an inability to digest sucrose and some of the glycosidic bonds in starch, both carbohydrates that are not part of the traditional Inuit diet. A recent, unpublished study found the variant to be associated with lower BMI, body fat percentage, bodyweight, and lipid levels independent of the lower intake of refined sugar. This might be explained by differences in the metabolism of carbohydrates and in the gut microbiota. The healthier phenotype was confirmed by a SI knockout mouse model, which furthermore interestingly indicated that the variant might alter food and taste preferences. It is anticipated that the drastic increase in type 2 diabetes in Greenland can be explained at least partly by the complex interaction between lifestyle and genetics. Therefore, the aim is to investigate if metabolic and microbial differences can explain the healthier phenotype of the homozygous carriers of the SI variant than wildtype individuals amd perform a 3-day cross-over dietary intervention using assigning subjects to a traditional Greenlandic diet and a Western diet. Moreover, the aim is to assess whether their food and taste preferences are different. The study will help us to understand the complex interactions between lifestyle, behavior, genetics, the microbiota and the host metabolism.


Description:

In this human study, effects of the SI knockout variant on metabolism, dietary habits and food preferences will be quantified. The study will be unique by being the first assessing the effect of a complete loss of SI function, which it is only feasible in Arctic populations. Differences between homozygous (HO) carriers and heterozygous (HE)/wildtype (WT) individuals are suspected to be large on a carbohydrate-rich diet and small on a traditional diet. The following hypotheses will be addressed: HO carriers metabolize carbohydrates differently than HE+WT individuals: 1. HO have a lower glycemic variability on their habitual diet than WT+HE. 2. HO have a lower glycemic variability on a starch and sucrose rich diet than WT+HE. 3. HO have a glycemic variability similar to WT+HE on a traditional diet low in carbohydrates. HO carriers have different food preferences than HE+WT individuals: 4. HO have a lower sweet taste preference compared to WT+HE. 5. HO perceive iso-intense solutions of sucrose, fructose, and glucose differently in sweet taste intensity and WT+HE will perceive them iso-intense. 6. HO consume less high-sugar-low-fat foods than WT+HE. 7. HO have similar intake and preference for high-sugar-high-fat foods as WT+HE. HO carriers have a microbiota different from HE+WT individuals: 8. Diversity and abundance of starch-fermenting bacteria is higher in HO than in WT+HE and the abundance of Parabacteroides is lower. 9. The increase in starch-fermenting bacteria as well as fecal and circulating levels of short chain fatty acids is larger for HO than in WT+HE on a starch and sucrose rich diet. 10. A diet low in carbohydrates will alter the microbiota similarly for HO and WT+HE.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date May 7, 2022
Est. primary completion date May 7, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Homozygous carriers of the c.273_274delAG variant in the SI-gene (cases) - Homozygous non-carriers of the c.273_274delAG variant in the SI-gene (controls) Exclusion Criteria: - Diagnosis of diabetes or pharmacological treatment of diabetes. - Gastrointestinal diseases such as inflammatory bowel disease, gastrointestinal cancer, and ulcer. Persons with mild gastrointestinal problems are not excluded, e.g. persons with lactose-intolerance who normally do not have any gastrointestinal problems. - Homozygous carriers of the TBC1D4 risk variant p.Arg684Ter. - Lack of compliance with the procedures in the study protocol, judged by Investigator. - For the homozygous carriers of the c.273_274delAG variant: rise in blood glucose in an oral sucrose tolerance test.

Study Design


Intervention

Other:
Cross-over study
Traditional Inuit Diet and Western Diet.

Locations

Country Name City State
Greenland Maniitsoq Healthcare Center Maniitsoq
Greenland Pikialaarfik, Greenland Institute of Natural Resources Nuussuaq

Sponsors (4)

Lead Sponsor Collaborator
Steno Diabetes Center Copenhagen Department of Food Science, University of Copenhagen, Steno Diabetes Center Greenland, The Novo Nordisk Foundation Center for Basic Metabolic Research

Country where clinical trial is conducted

Greenland, 

Outcome

Type Measure Description Time frame Safety issue
Other Body weight Weight (kg). Measured when the participant is wearing light underwear. Baseline (participant characteristics)
Other Height Height (cm). Measured when the participant is not wearing shoes. Baseline (participant characteristics)
Other Hip circumference Hip circumference (cm). Measured when the participant is wearing light underwear. Baseline (participant characteristics)
Other Waist circumference Waist circumference (cm). Measured when the participant is wearing light underwear. Baseline (participant characteristics)
Other Body composition Body fat percentage measured using a Tanita body composition analyser. Baseline (participant characteristics)
Other Plasma lipodomics. For future analyses The day before and the day after each dietary intervention period.
Other Plasma metabolomics. For future analyses The day before and the day after each dietary intervention period.
Other Plasma proteomics. For future analyses The day before and the day after each dietary intervention period.
Other Fecal lipodomics For future analyses The day before and the day after each dietary intervention period.
Other Fecal metabolomics. For future analyses The day before and the day after each dietary intervention period.
Other Fecal proteomics. For future analyses The day before and the day after each dietary intervention period.
Primary Glycemic variability during Western diet Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between. During the 3 days of intervention with Western diet.
Primary Glycemic variability during Inuit diet Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) during the whole study period, i.e. during both Western and Inuit diet and the wash-out period in between. During the 3 days of intervention with Inuit diet.
Secondary Sweet Bias Score As a food reward measure, explicit liking for foods with sweet relative to savory taste will be assessed using the Leeds Food Preference Questionnaire. A sweet bias score will be estimated, where a positive score indicates higher preference for sweet relative to savoury foods and a negative score indicates higher preference for savoury foods. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Fat Bias Score As a food reward measure, explicit liking for foods with high-fat relative to low-fat content will be assessed using the Leeds Food Preference Questionnaire. A fat bias score will be estimated, where a positive score indicates higher preference for high-fat relative to low-fat foods and a negative score indicates higher preference for low-fat foods. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary High-fat savory preference As a food reward measure, explicit liking for high-fat savory foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Low-fat savory preference As a food reward measure, explicit liking for low-fat savory foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary High-fat sweet preference As a food reward measure, explicit liking for high-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Low-fat sweet preference As a food reward measure, explicit liking for low-fat sweet foods will be assessed in the Leeds Food Preference Questionnaire. The average rating from 0-100 on the visual analogue scale is calculated for all four foods within the food category. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Implicit wanting score: High-fat savory foods As a food reward measure, implicit wanting for high-fat savory foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category.
Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Implicit wanting score: Low-fat savory foods As a food reward measure, implicit wanting for low-fat savory foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category.
Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Implicit wanting score: High-fat sweet foods As a food reward measure, implicit wanting for high-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category.
Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Implicit wanting score: Low-fat sweet foods As a food reward measure, implicit wanting for low-fat sweet foods will be assessed using the Leeds Food Preference Questionnaire.
The 'implicit wanting' score is calculated based on a combination of reaction time and choice or non-choice of foods in the forced choice paradigm. A positive score indicates a higher preference for this food category compared to the other food categories, and a negative score indicates a lower preference for this food category.
Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Habitual diet Habitual dietary intake will be assessed using a food frequency questionnaire. Macronutrient composition and content of sugar will be assessed as well as characterization of differences in food choice with respect to sweet foods and foods rich in starch. Intake will be expressed in g/day as well as E%. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Intake in a snacking test meal Using an ad libitum snacking test meal, preferences will be assessed for sweet-taste and content of sucrose and fat as well as other sweeteners than sucrose, e.g. honey. Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Sucrose sweetness sensitivity Ability to taste a difference between iso-intense solutions of sucrose and fructose+glucose using a 2-alternative forced choice test Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Sweet liking Hedonic rating of liking of iso-intense solutions of sucrose, fructose, glucose and fructose+glucose using a visual analogue scale (0-100 mm) Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Perceived intensity of sugars Hedonic rating of perceived intensity of iso-intense solutions of sucrose, fructose, glucose and fructose+glucos using a visual analogue scale (0-100 mm) Baseline (to assess differences between genotypes, independent of the intervention)
Secondary Plasma lipids Changes in fasting plasma measures of VLDL-cholesterol, LDL-cholesterol, HDL-cholesterol, total cholesterol, remnant cholesterol, and triglycerides The day before and the day after each dietary intervention period.
Secondary Serum insulin Changes in serum insulin. Fasting sample. The day before and the day after each dietary intervention period.
Secondary Plasma CRP Changes in plasma CRP. Fasting sample. The day before and the day after each dietary intervention period.
Secondary Plasma acetate Changes in plasma acetate. Fasting sample. The day before and the day after each dietary intervention period.
Secondary Plasma propionate Changes in plasma propionate. Fasting sample. The day before and the day after each dietary intervention period.
Secondary Plasma butyrate Changes in plasma butyrate. Fasting sample. The day before and the day after each dietary intervention period.
Secondary HbA1c Fasting glycated hemoglobin Baseline
Secondary Fecal acetate Changes in fecal acetate. Before and on the last day or on the day after each dietary intervention period.
Secondary Fecal propionate Changes in fecal propionate. Before and on the last day or on the day after each dietary intervention period.
Secondary Fecal butyrate Changes in fecal butyrate. Before and on the last day or on the day after each dietary intervention period.
Secondary Fecal pH pH of fecal samples. Before and on the last day or on the day after each dietary intervention period.
Secondary Changes in gut microbiota composition Changes in gut microbiota composition between baseline and end of each dietary intervention period. Microbiota composition is measured by genome sequencing fecal samples. Before and on the last day or on the day after each dietary intervention period.
Secondary Baseline gut microbiota composition Characterization of the gut microbiota composition. Microbiota composition is measured by genome sequencing fecal samples. Before intervention (baseline).
Secondary Fecal carbohydrates Content of carbohydrates in fecal samples and changes in this during the intervention periods. Before and on the last day or on the day after each dietary intervention period.
Secondary Glycemic variability during habitual diet Glycemic variability will be measured by mean amplitude of glycemic excursions (MAGE) Measured during 7 days of wash-out
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2